BEVERLY, Mass.--(BUSINESS WIRE)--Feb. 22, 2006--Inotek Pharmaceuticals Corporation announced today that it has commenced enrollment in a Phase 1 clinical trial for IMS, a novel therapeutic that interrupts signal transduction for inflammation. IMS represents the second compound to have entered clinical trials for Inotek. This study will evaluate the tolerability, safety, and pharmacokinetics of IMS in normal human volunteers. IMS is in development as an oral compound for the treatment of inflammatory bowel disease with initial efficacy trials planned for the treatment of ulcerative colitis. Phase 2 clinical trials are expected to commence toward the end of 2006.
